PE20020544A1 - Derivados de indolilmaleimida - Google Patents
Derivados de indolilmaleimidaInfo
- Publication number
- PE20020544A1 PE20020544A1 PE2001001093A PE2001001093A PE20020544A1 PE 20020544 A1 PE20020544 A1 PE 20020544A1 PE 2001001093 A PE2001001093 A PE 2001001093A PE 2001001093 A PE2001001093 A PE 2001001093A PE 20020544 A1 PE20020544 A1 PE 20020544A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- refers
- residue
- pirrol
- diona
- Prior art date
Links
- WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24640000P | 2000-11-07 | 2000-11-07 | |
| US28370501P | 2001-04-13 | 2001-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020544A1 true PE20020544A1 (es) | 2002-07-30 |
Family
ID=26937956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001093A PE20020544A1 (es) | 2000-11-07 | 2001-11-05 | Derivados de indolilmaleimida |
Country Status (30)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324064B (en) | 2002-04-03 | 2010-05-01 | Novartis Ag | Indolylmaleimide derivatives |
| AU2003240517A1 (en) * | 2002-06-05 | 2003-12-22 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
| JP2005531609A (ja) | 2002-06-05 | 2005-10-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体 |
| GB0303319D0 (en) * | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| CA2539132A1 (en) * | 2003-09-16 | 2005-03-24 | Garvan Institute Of Medical Research | Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith |
| JP2007509185A (ja) * | 2003-10-27 | 2007-04-12 | ノバルティス アクチエンゲゼルシャフト | βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体 |
| TWI344364B (en) * | 2003-11-10 | 2011-07-01 | Synta Pharmaceuticals Corp | Fused heterocyclic compounds |
| EP1709030B1 (en) * | 2004-01-19 | 2008-04-02 | Novartis AG | Indolylmaleimide derivatives |
| GB0401089D0 (en) * | 2004-01-19 | 2004-02-18 | Novartis Ag | Organic compounds |
| US20070232658A1 (en) * | 2004-04-08 | 2007-10-04 | Jurgen Wagner | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction |
| GB0410713D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| JP5289769B2 (ja) | 2004-12-08 | 2013-09-11 | ヨハネス、グーテンベルク−ウニフェルジテート、マインツ | ３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用 |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| GB0511060D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| DE602006019732D1 (de) | 2005-07-11 | 2011-03-03 | Novartis Ag | Indolylmaleimidderivate |
| EP3332807B1 (en) | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
| EP2275103B1 (en) | 2005-11-21 | 2014-04-23 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| GB0613162D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic compounds |
| EP2056831A2 (en) * | 2006-08-23 | 2009-05-13 | Novartis AG | Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases |
| AR063491A1 (es) * | 2006-10-20 | 2009-01-28 | Novartis Ag | Modificaciones de cristal |
| MX2009005945A (es) * | 2006-12-07 | 2009-06-17 | Novartis Ag | Uso de inhibidores de pkc en transplantes. |
| WO2008074752A2 (en) * | 2006-12-19 | 2008-06-26 | Novartis Ag | Indolylmaleimide derivatives as kinase inhibitors |
| BRPI0808354A2 (pt) * | 2007-03-09 | 2014-07-29 | Novartis Ag | Sais de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4 -il]-pirrola-2,5-diona |
| CA3080328C (en) | 2007-05-29 | 2022-06-21 | Novartis Ag | New indications for anti-il-1-beta therapy |
| RU2010116351A (ru) | 2007-09-27 | 2012-05-20 | Новартис АГ (CH) | Мониторинг лекарственных средств |
| WO2009060035A1 (en) | 2007-11-08 | 2009-05-14 | Novartis Ag | Gene expression signatures for chronic/sclerosing allograft nephropathy |
| CA2707554C (en) * | 2007-12-05 | 2015-06-30 | Gerd Dannhardt | Use of 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| US9752191B2 (en) | 2009-07-09 | 2017-09-05 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| RU2441000C2 (ru) * | 2009-11-27 | 2012-01-27 | Общество с ограниченной ответственностью "Молекулярные Технологии" | 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения |
| EP2343291A1 (en) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| EP2338486A1 (en) | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| KR20140107685A (ko) * | 2010-03-30 | 2014-09-04 | 노파르티스 아게 | 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제 |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2474541A1 (en) | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| CN102153605B (zh) * | 2011-03-02 | 2014-02-19 | 福建省微生物研究所 | 一种咪唑立宾的提纯方法 |
| UY34072A (es) * | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| CN103608349A (zh) | 2011-06-27 | 2014-02-26 | 诺瓦提斯公司 | 四氢-吡啶并-嘧啶衍生物的固体形式和盐 |
| GB201111427D0 (en) * | 2011-07-05 | 2011-08-17 | Amakem Nv | Novel bisindolylmaleimides, pan-pkc inhibitors |
| MX2014000338A (es) | 2011-07-08 | 2014-05-01 | Novartis Ag | Derivados de pirrolo-pirimidina novedoso. |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103987699A (zh) | 2011-10-21 | 2014-08-13 | 诺华股份有限公司 | 作为pi3k调节剂的喹唑啉衍生物 |
| WO2013082282A1 (en) | 2011-12-02 | 2013-06-06 | lNOVARTIS AG | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease. |
| CA2857302C (en) | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| HUE036953T2 (hu) | 2011-12-22 | 2018-08-28 | Novartis Ag | 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére |
| US20150148377A1 (en) | 2011-12-22 | 2015-05-28 | Novartis Ag | Quinoline Derivatives |
| EP2847191B1 (en) | 2012-05-09 | 2016-06-15 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| WO2014072911A1 (en) | 2012-11-07 | 2014-05-15 | Novartis Ag | Substituted indole derivatives |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| DK2925366T3 (en) | 2012-11-29 | 2018-06-06 | Novartis Ag | PHARMACEUTICAL COMBINATIONS |
| WO2014090396A2 (en) | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating cancer |
| WO2014090398A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| WO2015179773A1 (en) | 2014-05-22 | 2015-11-26 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
| SG11201600028YA (en) | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US9394281B2 (en) | 2014-03-28 | 2016-07-19 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US10004732B2 (en) | 2014-04-24 | 2018-06-26 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| JP2018522936A (ja) | 2015-08-14 | 2018-08-16 | ノバルティス アーゲー | ぶどう膜黒色腫の処置のためのｍｄｍ２阻害剤 |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| EP3187495A1 (en) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| US10995052B2 (en) | 2016-02-03 | 2021-05-04 | Galderma Research & Development | Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| WO2018175340A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
| WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP3972960A1 (en) | 2019-05-23 | 2022-03-30 | Novartis AG | Crystalline forms of a btk inhibitor |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7612609A (nl) | 1975-11-12 | 1977-05-16 | Schering Ag | Werkwijze voor het bereiden van 1,3-geoxyge- neerde 8(alpha)-ostratienen. |
| NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
| FR2637591B1 (fr) | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
| DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
| HK1038564A1 (zh) * | 1998-10-08 | 2002-03-22 | Smithkline Beecham Plc | 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮 |
| GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| CA2417277A1 (en) * | 2000-07-27 | 2002-02-07 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
-
2001
- 2001-11-05 CN CNB018199925A patent/CN1253449C/zh not_active Expired - Fee Related
- 2001-11-05 NZ NZ525656A patent/NZ525656A/xx not_active IP Right Cessation
- 2001-11-05 AT AT01993604T patent/ATE445613T1/de active
- 2001-11-05 CA CA002428133A patent/CA2428133C/en not_active Expired - Fee Related
- 2001-11-05 CZ CZ2003-1266A patent/CZ307144B6/cs not_active IP Right Cessation
- 2001-11-05 DK DK01993604T patent/DK1337527T3/da active
- 2001-11-05 RU RU2003115429/04A patent/RU2329263C2/ru not_active IP Right Cessation
- 2001-11-05 IL IL15561801A patent/IL155618A0/xx active IP Right Grant
- 2001-11-05 ES ES01993604T patent/ES2332770T3/es not_active Expired - Lifetime
- 2001-11-05 DE DE60140201T patent/DE60140201D1/de not_active Expired - Lifetime
- 2001-11-05 AU AU2002221810A patent/AU2002221810B2/en not_active Ceased
- 2001-11-05 SK SK546-2003A patent/SK287919B6/sk not_active IP Right Cessation
- 2001-11-05 SG SG200502844-4A patent/SG159378A1/en unknown
- 2001-11-05 AU AU2181002A patent/AU2181002A/xx active Pending
- 2001-11-05 PE PE2001001093A patent/PE20020544A1/es not_active Application Discontinuation
- 2001-11-05 EP EP01993604A patent/EP1337527B1/en not_active Expired - Lifetime
- 2001-11-05 NZ NZ535616A patent/NZ535616A/xx not_active IP Right Cessation
- 2001-11-05 JP JP2002541095A patent/JP4234426B2/ja not_active Expired - Fee Related
- 2001-11-05 PL PL361409A patent/PL208794B1/pl unknown
- 2001-11-05 MX MXPA03004037A patent/MXPA03004037A/es active IP Right Grant
- 2001-11-05 PT PT01993604T patent/PT1337527E/pt unknown
- 2001-11-05 WO PCT/EP2001/012785 patent/WO2002038561A1/en active Application Filing
- 2001-11-05 EP EP09151894A patent/EP2070921A1/en not_active Withdrawn
- 2001-11-05 SI SI200130954T patent/SI1337527T1/sl unknown
- 2001-11-05 BR BRPI0115193A patent/BRPI0115193B1/pt not_active IP Right Cessation
- 2001-11-05 HU HU0301651A patent/HU228999B1/hu not_active IP Right Cessation
- 2001-11-05 AR ARP010105176A patent/AR035211A1/es not_active Application Discontinuation
- 2001-11-05 KR KR1020067017472A patent/KR100916613B1/ko not_active Expired - Fee Related
- 2001-11-05 KR KR1020037005805A patent/KR100748386B1/ko not_active Expired - Fee Related
- 2001-11-05 KR KR1020087002849A patent/KR20080014934A/ko not_active Ceased
- 2001-11-06 MY MYPI20015097A patent/MY127157A/en unknown
- 2001-11-06 MY MYPI20055681A patent/MY139979A/en unknown
- 2001-11-07 TW TW096118830A patent/TW200738687A/zh unknown
- 2001-11-07 TW TW090127656A patent/TWI290553B/zh not_active IP Right Cessation
-
2003
- 2003-04-28 IL IL155618A patent/IL155618A/en not_active IP Right Cessation
- 2003-05-06 NO NO20032034A patent/NO327427B1/no not_active IP Right Cessation
-
2005
- 2005-06-01 AU AU2005202387A patent/AU2005202387B2/en not_active Ceased
-
2007
- 2007-04-10 IL IL182428A patent/IL182428A0/en unknown
-
2008
- 2008-02-14 RU RU2008105345/04A patent/RU2008105345A/ru not_active Application Discontinuation
-
2009
- 2009-11-25 CY CY20091101228T patent/CY1110564T1/el unknown
-
2010
- 2010-03-11 EC EC2010004578A patent/ECSP104578A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020544A1 (es) | Derivados de indolilmaleimida | |
| PE20020131A1 (es) | Derivados de pirazol | |
| PE20030137A1 (es) | Derivados antimicrobianos de quinolona | |
| PE20021056A1 (es) | Derivados de pirazol | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| PE20020589A1 (es) | 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas | |
| PE20001093A1 (es) | 3-amino-4-aril-maleimidas como inhibidores de gsk-3 | |
| AR036906A1 (es) | Compuestos de imidazopiridin como moduladores del receptor 5-ht4 | |
| PE20011089A1 (es) | Tioamidas de oxazolidinona con sustituyentes de piperazin-amida | |
| PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
| AR057107A2 (es) | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos | |
| AR032466A1 (es) | Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos | |
| PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
| FR2673427B1 (fr) | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. | |
| PE20020467A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina | |
| AR018915A1 (es) | Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos | |
| CO4970807A1 (es) | Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos | |
| AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene | |
| PE20040757A1 (es) | Derivados de benzoxazina | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| PE20080311A1 (es) | Derivados de oxadiazol como agentes afines a receptores nicotinicos | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20020444A1 (es) | Antagonistas de receptores de taquiquinina zwitterionica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |